Edition:
United States

Alexion Pharmaceuticals Inc (ALXN.OQ)

ALXN.OQ on NASDAQ Stock Exchange Global Select Market

116.17USD
4:00pm EDT
Change (% chg)

$0.17 (+0.15%)
Prev Close
$116.00
Open
$118.47
Day's High
$118.47
Day's Low
$115.70
Volume
513,682
Avg. Vol
561,025
52-wk High
$149.17
52-wk Low
$102.21

Chart for

About

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company's clinical development programs include Soliris (eculizumab... (more)

Overall

Beta: 0.91
Market Cap(Mil.): $25,851.66
Shares Outstanding(Mil.): 222.86
Dividend: --
Yield (%): --

Financials

  ALXN.OQ Industry Sector
P/E (TTM): -- 28.29 30.45
EPS (TTM): -0.08 -- --
ROI: -0.13 12.92 12.63
ROE: -0.18 14.94 14.82

BRIEF-Alexion Reports Q1 Results And Positive Topline Data From ALXN1210 Phase 3 PNH Switch Study

* ALEXION REPORTS FIRST QUARTER 2018 RESULTS AND POSITIVE TOPLINE DATA FROM ALXN1210 PHASE 3 PNH SWITCH STUDY

Apr 26 2018

BRIEF-Alexion Says No Compulsory License Of Soliris Was Requested Or Granted In Brazil

* ALEXION PROVIDES STATEMENT ON SUPERIOR COURT OF JUSTICE (STJ) DECISION IN BRAZIL INVOLVING SOLIRIS® (ECULIZUMAB)

Apr 20 2018

Deals of the day-Mergers and acquisitions

April 11 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday:

Apr 11 2018

Biotech M&A rolls on as Alexion snaps up Wilson for $855 million

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Apr 11 2018

Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

Alexion Pharmaceuticals has agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.

Apr 11 2018

UPDATE 2-Biotech M&A rolls on as Alexion snaps up Wilson for $855 mln

* U.S. company says first step in rebuilding pipeline (Adds latest shares, analyst reaction)

Apr 11 2018

Alexion to buy Swedish biotech Wilson Therapeutics for $855 mln

April 11 Alexion Pharmaceuticals said on Wednesday it had agreed to buy Sweden's Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million) to boost its line-up of rare disease drugs.

Apr 11 2018

BRIEF-Alexion To Acquire Wilson Therapeutics

* SAYS ALEXION WILL ACQUIRE WILSON THERAPEUTICS THROUGH A TENDER OFFER

Apr 11 2018

BRIEF-Alexion Pharmaceuticals Says CEO Ludwig Hantson's Total FY 2017 Compensation Was $15.3 Mln

* ALEXION PHARMACEUTICALS SAYS CEO LUDWIG HANTSON'S TOTAL FY 2017 COMPENSATION WAS $15.3 MILLION - SEC FILING

Mar 28 2018

S&P falls for fourth day as Mueller subpoena weighs

NEW YORK The S&P 500 ended slightly lower on Thursday after a report that U.S. Special Counsel Robert Mueller had issued a subpoena for documents related to U.S. President Donald Trump's businesses offset strong jobs and manufacturing data. | Video

Mar 15 2018

Competitors

Earnings vs. Estimates